Subtopic Deep Dive

← Organoselenium and organotellurium chemistry

Chemopreventive Organoselenium Compounds
Research Guide

What is Chemopreventive Organoselenium Compounds?

Chemopreventive organoselenium compounds are synthetic or naturally derived selenium-containing molecules that prevent cancer initiation and progression through antioxidant, prooxidant, and enzyme-inducing mechanisms.

These compounds, including ebselen and selenides, exhibit dual redox activity modulating oxidative stress in cancer cells (Misra et al., 2015; 303 citations). Research spans Phase II enzyme induction, apoptosis in tumor models, and clinical potential (Álvarez et al., 2018; 167 citations). Over 10 key papers from 2007-2021 document their synthesis and toxicology, with 95-327 citations each.

Curated Papers

Key Challenges

Why It Matters

Organoselenium compounds like ebselen target redox pathways for cancer prevention, showing efficacy in prostate (PC-3) and breast (MCF-7) cell lines via superoxide generation (Plano et al., 2010). Selenides and diselenides induce apoptosis and inhibit tumor growth in animal models, offering dietary intervention strategies (Álvarez et al., 2018). Updates on toxicology support safer pharmaceutical development, reducing oxidative stress-related risks (Nogueira et al., 2021). Clinical trials potential stems from GPx-mimetic activity (Azad and Tomar, 2014).

Key Research Challenges

Redox Toxicity Balance

Compounds like ebselen show antioxidant benefits at low doses but prooxidant toxicity at high concentrations, complicating therapeutic windows (Misra et al., 2015). Species-dependent effects challenge safe dosing (Azad and Tomar, 2014).

Scalable Green Synthesis

Ecofriendly methods for selenides and isoselenocyanates lag behind demand for clinical-grade compounds (Santoro et al., 2014). Heterocycle synthesis yields remain low despite pharmaceutical promise (Garud et al., 2007).

Clinical Translation Barriers

Animal model efficacy in tumor prevention does not consistently predict human trials due to bioavailability issues (Nogueira et al., 2021). Long-term toxicology data for diselenides is insufficient (Santi et al., 2021).

Essential Papers

Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathways

Gajendra Kumar Azad, Raghuvir Singh Tomar · 2014 · Molecular Biology Reports · 327 citations

Redox-Active Selenium Compounds—From Toxicity and Cell Death to Cancer Treatment

Sougat Misra, Mallory Boylan, Arun Kumar Selvam et al. · 2015 · Nutrients · 303 citations

Selenium is generally known as an antioxidant due to its presence in selenoproteins as selenocysteine, but it is also toxic. The toxic effects of selenium are, however, strictly concentration and c...

Toxicology and pharmacology of synthetic organoselenium compounds: an update

Cristina W. Nogueira, Nilda Vargas Barbosa, João Batista Teixeira da Rocha · 2021 · Archives of Toxicology · 205 citations

“The green side of the moon: ecofriendly aspects of organoselenium chemistry”

Stefano Santoro, Juliano B. Azeredo, Vanessa Nascimento et al. · 2014 · RSC Advances · 184 citations

Key aspects for the development of a greener synthesis and the use of the organoselenium compounds.

Selenides and Diselenides: A Review of Their Anticancer and Chemopreventive Activity

M. Álvarez, Wesam Ali, Małgorzata Anna Marć et al. · 2018 · Molecules · 167 citations

Selenium and selenocompounds have attracted the attention and the efforts of scientists worldwide due to their promising potential applications in cancer prevention and/or treatment. Different orga...

Ebselen and Analogues: Pharmacological Properties and Synthetic Strategies for Their Preparation

Claudio Santi, Cecilia Scimmi, Luca Sancineto · 2021 · Molecules · 111 citations

Ebselen is the leader of selenorganic compounds, and starting from its identification as mimetic of the key antioxidant enzyme glutathione peroxidase, several papers have appeared in literature cla...

Isoselenocyanates: A Powerful Tool for the Synthesis of Selenium-Containing Heterocycles

Dinesh R. Garud, Mamoru Koketsu, Hideharu Ishihara · 2007 · Molecules · 108 citations

Selenium-containingheterocyclic compounds have been well recognized, not only because of their remarkable reactivities and chemical properties, but also because of their diverse pharmaceutical appl...

Reading Guide

Foundational Papers

Start with Azad and Tomar (2014; 327 citations) for ebselen mechanisms as GPx mimetic; Plano et al. (2010; 95 citations) for library screening in cancer cells; Garud et al. (2007; 108 citations) for synthesis basics.

Recent Advances

Nogueira et al. (2021; 205 citations) updates toxicology; Santi et al. (2021; 111 citations) covers ebselen analogs; Álvarez et al. (2018; 167 citations) reviews anticancer selenides.

Core Methods

Redox modulation via GPx mimicry (Azad and Tomar, 2014); superoxide generation assays (Plano et al., 2010); isoselenocyanate heterocycle synthesis (Garud et al., 2007); Phase II enzyme induction in models (Misra et al., 2015).

How PapersFlow Helps You Research Chemopreventive Organoselenium Compounds

Discover & Search

PapersFlow's Research Agent uses searchPapers and citationGraph to map high-citation works like Misra et al. (2015; 303 citations) on redox-active selenium, then findSimilarPapers uncovers analogs in ebselen toxicology. exaSearch reveals 250M+ OpenAlex papers on Phase II induction beyond the top 10.

Analyze & Verify

Analysis Agent applies readPaperContent to extract mechanisms from Azad and Tomar (2014), verifies claims with CoVe chain-of-verification, and runs PythonAnalysis on dose-response data from Plano et al. (2010) for IC50 stats in PC-3 cells. GRADE grading scores evidence strength for apoptosis induction (Álvarez et al., 2018).

Synthesize & Write

Synthesis Agent detects gaps in green synthesis post-Santoro et al. (2014), flags contradictions in prooxidant effects (Misra et al., 2015 vs. Nogueira et al., 2021). Writing Agent uses latexEditText, latexSyncCitations for 10-paper reviews, and latexCompile for mechanism diagrams via exportMermaid.

Use Cases

"Analyze IC50 trends in organoselenium libraries for PC-3 prostate cancer cells."

Research Agent → searchPapers('Plano 2010 organoselenium PC-3') → Analysis Agent → readPaperContent + runPythonAnalysis(pandas plot IC50 vs. structure) → matplotlib dose-response graph.

"Draft LaTeX review on ebselen analogs with citations."

Synthesis Agent → gap detection (Santi 2021) → Writing Agent → latexEditText(structure review) → latexSyncCitations(10 papers) → latexCompile(PDF with redox pathway figure).

"Find GitHub code for organoselenium QSAR models."

Research Agent → searchPapers('organoselenium QSAR') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → exportCsv(model parameters from Álvarez 2018 analogs).

Automated Workflows

Deep Research workflow scans 50+ papers on chemopreventive selenium, chaining citationGraph → DeepScan for 7-step verification of toxicology claims (Nogueira et al., 2021). Theorizer generates hypotheses on diselenide Phase II induction from Misra et al. (2015) + animal data, outputting Mermaid causal diagrams.

Try Doxa for Chemopreventive Organoselenium Compounds Research

Frequently Asked Questions

What defines chemopreventive organoselenium compounds?

They are selenium molecules like ebselen and selenides that prevent cancer via redox modulation, enzyme induction, and apoptosis (Misra et al., 2015; Álvarez et al., 2018).

What are key synthesis methods?

Isoselenocyanates enable heterocycle synthesis (Garud et al., 2007); green approaches reduce waste in diselenide production (Santoro et al., 2014).

What are the top papers?

Azad and Tomar (2014; 327 citations) on ebselen mechanisms; Misra et al. (2015; 303 citations) on redox toxicity; Álvarez et al. (2018; 167 citations) on selenides.

What open problems exist?

Balancing redox toxicity for clinical use (Nogueira et al., 2021); scaling green synthesis (Santoro et al., 2014); validating animal tumor prevention in humans.